Dupixent COPD Approval Could Be Delayed, Regeneron Cautions

The US Food and Drug Administration has requested additional efficacy information on the supplemental filing in the potentially large new indication.

hour glass
Regeneron signaled a possible delay for Dupixent in COPD • Source: Shutterstock

Regeneron Pharmaceuticals, Inc. has many moving parts to prioritize this year as it transitions patients to a new version of its blockbuster ophthalmology drug Eylea (aflibercept), expands the use of Dupixent (dupilumab) to a potentially big new indication in chronic obstructive pulmonary disease (COPD), and advances an interesting pipeline that includes therapies for obesity, cancer, allergy and hearing loss.

CEO Leonard Schleifer cautioned investors during a first quarter sales and earnings call on 2 May that a US Food...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Immunological

Sjögren’s Success For Ianalumab Shores Up Novartis’s Pipeline-In-A-Product Plans

 

Novartis has strengthened its argument that ianalumab, its BAFF-R inhibitor and ADCC-mediated B-cell depletor candidate, has PIP potential with successful topline results in two Phase III Sjögren’s syndrome trials, after recently dropping the product in hidradenitis suppurativa.

Novartis’s ‘Pipeline-In-A-Product’ Assets Progressing Well

 
• By 

CMO Shreeram Aradhye talks to Scrip about the promise shown by ianalumab, remibrutinib and a next-generation CAR-T for immunological disorders.

AbbVie Raises Full-Year Sales Guidance On Skyrizi/Rinvoq Strength

 
• By 

AbbVie now expects the two Humira successors to bring in $25bn this year. On its Q2 earnings call, the firm also pointed to strength in neuroscience, with 24% growth.

Argenx Powers Ahead With Vyvgart’s Prefilled Syringe Launch

 

The Netherlands-headquartered company is enjoying huge success with Vyvgart in two autoimmune conditions, with a new prefilled syringe version reaching more patient groups.

More from Therapy Areas

Genmab/AbbVie’s Epkinly Likely To See Label Expansion After Phase III Win

 

The FDA is expected to rule on the anti-CD20xCD3 bispecific combined with rituximab/lenalidomide in second-line follicular lymphoma in November.

Sanofi’s Sarclisa Wins Another EU Multiple Myeloma Nod In Its Unequal Battle With J&J’s Darzalex

 

The French drugmaker's anti-CD38 antibody has racked up another approval in first-line multiple myeloma, but it marks a small victory while the company develops a subcutaneous version to help level the field with J&J’s Darzalex.

Jazz’s Modeyso Approved For Rare Glioma With Expansion Targeted

 

The accelerated approval came three months after Jazz completed the acquisition of Modeyso’s developer, Chimerix.